The average sentiment for articles published by this News Source are below.

Anger: Red
Disgust: Olive
Fear: Green
Joy: Gold
Sadness: Blue
View Post

ITUS Corporation Licenses CAR-T Technology from The Wistar Institute

In Business, Government, Healthcare, Legal, Science & Nature by ITUS CorporationLeave a Comment

Tech News Keywords: , , , ,

SAN JOSE, Calif., Nov. 14, 2017 /PRNewswire/ -- ITUS Corporation (NASDAQ: ITUS) today announced that it has executed an exclusive worldwide license agreement with The Wistar Institute for a Chimeric Antigen Receptor T-Cell (CAR-T) technology aimed initially at treating ovarian cancer, and eventually additional solid tumors.   ITUS has formed a subsidiary, Certainty Therapeutics, Inc., to develop and commercialize the innovative CAR-T technology. The Wistar Institute is a founding member of Certainty Therapeutics along with majority owner ITUS. Dr. Amit Kumar, President and CEO of ITUS stated, "We are very pleased to have entered into this new rela... Read More
View Post

ITUS Corporation Pays Off Secured Debenture

In Healthcare, Legal by ITUS CorporationLeave a Comment

Tech News Keywords: ,

ITUS Corporation Pays Off Secured Debenture SAN JOSE, CA -- (Marketwired) -- 10/27/17 -- ITUS Corporation (NASDAQ: ITUS) today announced that it has satisfied all obligations under its secured debenture by paying the creditor the outstanding principal and interest in cash ahead of its due date. As a result of this debt retirement, ITUS currently has no significant debt obligations. "We are very pleased to be in a position to pay off our secured debt obligation, while still maintaining adequate capital to maintain our current operations and to be essentially debt-free," stated Dr. Amit Kumar, Chief Executive Officer of ITUS. Dr. Kumar added, "Our recent successful financing has strengthened ... Read More
View Post

ITUS Corporation Completes At-the-Market Offering

In Business, Government, Healthcare, Legal by ITUS CorporationLeave a Comment

Tech News Keywords: , ,

ITUS Corporation Completes At-the-Market Offering SAN JOSE, CA -- (Marketwired) -- 10/02/17 -- ITUS Corporation (NASDAQ: ITUS) (the "Company") completed an offering of all of its shares of its common stock, par value $0.01 (the "Common Stock") pursuant to its recently announced at-the-market equity program generating gross proceeds of approximately $3.7 million. FBR Capital Markets & Co. acted as sales agent for the program. The program commenced on September 29, 2017 and was fully sold by the close of market on September 29, 2017. The Company is no longer offering shares of Common Stock under this program. "We were very pleased to see the substantial demand for our stock and support for ou... Read More
View Post

ITUS Presentation to Annual Meeting of Stockholders

In Government, Healthcare, Legal, Science & Nature by ITUS CorporationLeave a Comment

Tech News Keywords: , , ,

ITUS Presentation to Annual Meeting of Stockholders SAN JOSE, CA -- (Marketwired) -- 09/26/17 -- ITUS Corporation (NASDAQ: ITUS) today announced that the presentation given by its Chief Executive Officer, Dr. Amit Kumar, at its Annual Meeting of Stockholders on September 22, 2017 has been placed on the Company's website. It can be viewed at http://ir.ituscorp.com/corporate-presentation. Highlights of the presentation include: The science behind Cchek™ The use of our proprietary Artificial Intelligence in cancer screening Summary of our data, showing 90% and greater sensitivi... Read More
View Post

ITUS Corporation to Present at the 2017 Disruptive Growth Company Showcase NYC Presented by SeeThruEquity and RHK Capital

In Business, Government, Healthcare, Legal by ITUS CorporationLeave a Comment

Tech News Keywords: , , , , , , ,

ITUS Corporation to Present at the 2017 Disruptive Growth Company Showcase NYC Presented by SeeThruEquity and RHK Capital NEW YORK, NY / ACCESSWIRE / September 25, 2017 / ITUS Corporation (NASDAQ: ITUS) announced today that it will be presenting at the 2017 Disruptive Growth Company Showcase NYC at 2:30 PM EDT/ 11:30 AM PDT on September 27, 2017 at the Grand Hyatt 109 E 42nd St. Dr. Amit Kumar, CEO of ITUS, will be presenting, as well as meeting with investors. Each company will be provided with a 30-minute time slot to present to an audience of investors and industry professionals and company management will also be available for one-on-one meetings with institutional investors. ... Read More
View Post

ITUS Provides Update on Cancer Detection Technology and New CAR-T Initiative for Ovarian Cancer

In Business, Government, Healthcare, Legal by ITUS CorporationLeave a Comment

Tech News Keywords: , , , , , , ,

ITUS Provides Update on Cancer Detection Technology and New CAR-T Initiative for Ovarian Cancer SAN JOSE, CA -- (Marketwired) -- 09/21/17 -- ITUS Corporation (NASDAQ: ITUS) today provides a corporate update before its Annual Meeting of Stockholders to be held on September 22, 2017. ITUS's wholly owned subsidiary Anixa Diagnostics, recently renewed its research agreement with The Wistar Institute for continued development of Cchek™, its early cancer detection technology. Dr. Amit Kumar, President and CEO of ITUS stated, "We continue to make progress in our R&D efforts as we work with our partners, MD Anderson, U. Pennsylvania's Abramson Cancer Center, Delaware Valley Urology, Virtua Ho... Read More
View Post

ITUS Corporation Announces Issuance of Patent on Cancer Detection Technology

In Government, Healthcare, Legal by ITUS CorporationLeave a Comment

Tech News Keywords: , ,

ITUS Corporation Announces Issuance of Patent on Cancer Detection Technology SAN JOSE, CA -- (Marketwired) -- 09/18/17 -- ITUS Corporation (NASDAQ: ITUS), today announced that the United States Patent and Trademark Office ("USPTO") has issued U.S. Patent 9,739,783, to inventors Dr. Amit Kumar, Chief Executive Officer, and John Roop, VP of Engineering, of ITUS Corporation. ITUS's early cancer detection technology is being developed by its wholly owned subsidiary, Anixa Diagnostics Corporation. Dr. Kumar stated, "This is the first patent to issue of several patents that we expect to issue garnering protection of our cancer detection technology. The claims of this patent were allowed in May of... Read More
View Post

The Wistar Institute and ITUS Corporation Renew Collaborative Research Agreement

In Business, Education, Government, Healthcare, Legal by ITUS Corporation

Tech News Keywords: , , ,

The Wistar Institute and ITUS Corporation Renew Collaborative Research Agreement LOS ANGELES, CA -- (Marketwired) -- 08/07/17 -- ITUS Corporation (NASDAQ: ITUS) today announced that ITUS and The Wistar Institute have renewed their collaboration for the development of Cchek™, the company's early cancer detection technology. Dr. Amit Kumar, ITUS's Chairman and CEO, stated, "We are pleased to continue our relationship with the Wistar Institute as we continue to advance our early cancer detection technology. Wistar's R&D support has been and continues to be valuable to the development of Cchek™." Dr. Kumar continued, "Over the last two years working with Wistar, we have learned a... Read More
View Post

Lew Titterton re-joins ITUS Corporation’s Board of Directors

In Business, Education, Government, Healthcare, Legal by ITUS Corporation

Tech News Keywords: , , , ,

Lew Titterton re-joins ITUS Corporation's Board of Directors LOS ANGELES, CA -- (Marketwired) -- 07/18/17 -- ITUS Corporation (NASDAQ: ITUS) today announced that Lew Titterton has been appointed to its Board of Directors. Mr. Titterton rejoins the ITUS Board of Directors after having previously served as a Director from August 2010 through August 2016, the last four years of which as Chairman of the Board. He also served as a Director from July 1999 to January 2003. Mr. Titterton's background is in high technology with an emphasis on health care. He is currently the Chairman of the Board of NYMED, Inc., a diversified health services company. Mr. Titterton founded MedE America, Inc. in 1986 ... Read More
View Post

ITUS Appoints Dr. Amit Kumar as New CEO and Announces Management Changes

In Business, Education, Finance, Government, Healthcare, Legal, Start Up by ITUS Corporation

Tech News Keywords: , , , , ,

ITUS Appoints Dr. Amit Kumar as New CEO and Announces Management Changes LOS ANGELES, CA -- (Marketwired) -- 07/07/17 -- ITUS Corporation (NASDAQ: ITUS) today announced that its Board of Directors has appointed Dr. Amit Kumar as its new President and Chief Executive Officer. Dr. Kumar replaces Mr. Robert Berman, who has resigned as President, CEO and as a Director. In addition, Mike Catelani, ITUS' CFO, has been promoted to Chief Operating Officer (COO). Dr. Kumar has served as the Company's Executive Chairman for the past year, and has been a Director since joining the Company in 2012. Amit is the inventor of our Cchek™ cancer testing platform, and has been leading its development since ... Read More
View Post

ITUS Corporation to Present at the 7th Annual LD Micro Conference

In Healthcare, Legal by ITUS Corporation

Tech News Keywords: , ,

ITUS Corporation to Present at the 7th Annual LD Micro Conference LOS ANGELES, CA -- (Marketwired) -- 06/01/17 -- ITUS Corporation ("ITUS") (NASDAQ: ITUS), a company using the power of the immune system to diagnose cancer, today announced that it will present at the 7th Annual LD Micro Conference at the Luxe Sunset Bel Air Hotel in Los Angeles. The ITUS presentation will take place on Tuesday, June 6, at 9:30 am Pacific Time. LD Micro was founded in 2006 with the sole purpose of being an independent resource in the microcap space. What started out as a newsletter highlighting unique companies has transformed into an event platform hosting influential micro... Read More
View Post

ITUS Corporation to Present at WallStreet Research Hosted Event on May 31 in Los Angeles

In Healthcare, Legal by ITUS Corporation

Tech News Keywords: ,

ITUS Corporation to Present at WallStreet Research Hosted Event on May 31 in Los Angeles LOS ANGELES, CA -- (Marketwired) -- 05/30/17 -- ITUS Corporation ("ITUS") (NASDAQ: ITUS), a company using the power of the immune system to diagnose cancer, today announced that it will present at an investor event hosted by WallStreet Research in Los Angeles on May 31, 2017. The event will be held at Skylight Gardens in Westwood, with registration for the event beginning at 12:30 pm Pacific Time. WallStreet Research, which specializes in bringing undervalued companies to the attention of the investment community, hosts investor events in select cities throughout the U.S. and pro... Read More
View Post

ITUS Corporation Successfully Completes $3.6 Million Public Offering

In Healthcare, Legal by ITUS Corporation

Tech News Keywords: , ,

ITUS Corporation Successfully Completes $3.6 Million Public Offering LOS ANGELES, CA -- (Marketwired) -- 05/16/17 -- ITUS Corporation ("ITUS") (NASDAQ:ITUS), a company using the power of the immune system to diagnose cancer, today announced that it has successfully completed its recently announced registered public offering of approximately 3.4 million shares of the company's common stock, generating gross proceeds of approximately $3.6 million. Dawson James Securities, Inc. acted as exclusive placement agent for the offering. "The proceeds from this public offering, together with the recently completed rights offering, should provide the company with sufficient capital to pay off its indebtedness... Read More
View Post

ITUS Corporation Announces Pricing of Public Offering of up to 3.5 million shares of Common Stock

In Business, Healthcare, Legal by ITUS Corporation

Tech News Keywords: , , ,

ITUS Corporation Announces Pricing of Public Offering of up to 3.5 million shares of Common Stock LOS ANGELES, CA -- (Marketwired) -- 05/11/17 -- ITUS Corporation ("ITUS") (NASDAQ: ITUS), a company using the power of the immune system to diagnose cancer, today announced that it has priced a best efforts registered public offering of up to an aggregate of 3.5 million shares of the company's common stock at a price to the public of $1.05 per share. The offering is expected to close on or about May 16, 2017, subject to the satisfaction of customary closing conditions. Dawson James Securities, Inc., is acting as exclusive placement agent for the offering. The aggregate gross proceeds of ... Read More
View Post

ITUS Corporation Announces Proposed Public Offering of Common Stock

In Business, Healthcare, Legal by ITUS Corporation

Tech News Keywords: , , ,

ITUS Corporation Announces Proposed Public Offering of Common Stock LOS ANGELES, CA -- (Marketwired) -- 05/10/17 -- ITUS Corporation (ITUS) (NASDAQ: ITUS), a company using the power of the immune system to diagnose cancer, today announced a proposed registered public offering of its common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Dawson James Securities, Inc., is acting as exclusive placement agent for the offering. ITUS intends to use the net proceeds from the offering, if comp... Read More
View Post

ITUS Receives Notice of Allowance for First Cancer Technology Patent

In Business, Healthcare, Legal by ITUS Corporation

Tech News Keywords: , , ,

ITUS Receives Notice of Allowance for First Cancer Technology Patent LOS ANGELES, CA -- (Marketwired) -- 05/10/17 -- ITUS Corporation ("ITUS") (NASDAQ: ITUS), a company using the power of the immune system to diagnose cancer, today announced that the United States Patent and Trademark Office ("USPTO") has issued a Notice of Allowance on the first patent filed by the company to protect its cancer detection technology. ITUS is developing a platform called Cchek™ from which it expects to launch a series of non-invasive, inexpensive cancer diagnostic blood tests. Robert Berman, ITUS's President and Chief Executive Officer stated: "This is the first of what we hope will... Read More
View Post

ITUS Extends its Collaboration with Virtua Healthcare System

In Business, Education, Healthcare, Legal by ITUS Corporation

Tech News Keywords: , , , , ,

ITUS Extends its Collaboration with Virtua Healthcare System LOS ANGELES, CA -- (Marketwired) -- 05/09/17 -- ITUS Corporation ("ITUS") (NASDAQ: ITUS), a company using the power of the immune system to diagnose cancer, today announced that it has extended its collaboration with Virtua Healthcare System. Pursuant to the extension, Virtua will continue to provide patient samples for ITUS's ongoing cancer study through May of 2018. Robert Berman, ITUS's President and Chief Executive Officer stated: "Virtua has been an invaluable partner in working with us on our study, and the samples they will provide over the next year will help us reach th... Read More
View Post

ITUS Presents at American Association of Cancer Research Conference

In Business, Healthcare, Legal by ITUS Corporation

Tech News Keywords: , , , , ,

ITUS Presents at American Association of Cancer Research Conference LOS ANGELES, CA -- (Marketwired) -- 04/06/17 -- ITUS Corporation ("ITUS") (NASDAQ: ITUS), a company using the power of the immune system to diagnose cancer, announced that its presentation at the American Association of Cancer Research conference in Washington, D.C. is now available. The presentation is highly technical in nature, and is geared to the scientific community. To receive an emailed copy of the presentation, please email us at AACRposter@ITUScorp.com and include your name, title, and contact information.... Read More
View Post

ITUS Announces Closing of Rights Offering

In Business, Healthcare, Legal by ITUS Corporation

Tech News Keywords: , , , , ,

ITUS Announces Closing of Rights Offering LOS ANGELES, CA -- (Marketwired) -- 04/04/17 -- ITUS Corporation ("ITUS") (NASDAQ: ITUS), announced that its rights offering of common shares closed today, raising gross proceeds of approximately $4.7 million before payment of dealer manager fee and other expenses, through the issuance of 1,989,207 shares of common stock. Robert Berman, ITUS's President and CEO, stated, "Proceeds from the rights offering will enable us to continue the development of our Cchek™ cancer detection technology and assist us in meeting our corporate obligations. We are thankful to our shareholders that parti... Read More
View Post

ITUS Early Cancer Detection Biomarker Study Expands to Include Abramson Cancer Center Researchers

In Business, Education, Healthcare, Legal by ITUS Corporation

Tech News Keywords: , , ,

ITUS Early Cancer Detection Biomarker Study Expands to Include Abramson Cancer Center Researchers LOS ANGELES, CA -- (Marketwired) -- 03/20/17 -- ITUS Corporation ("ITUS") (NASDAQ: ITUS), a company using the power of the immune system to diagnose cancer, today announced that Dr. Ari Brooks, Director of the Integrated Breast Center at Pennsylvania Hospital and a researcher in the Abramson Cancer Center at the University of Pennsylvania, https://www.pennmedicine.org/cancer/about, has joined ITUS's early cancer detection biomarker study. The study will use patient blood samples ... Read More
View Post

ITUS Rights Offering Materials Available for Shareholders of Record

In Business, Healthcare, Legal by ITUS Corporation

Tech News Keywords: , , ,

ITUS Rights Offering Materials Available for Shareholders of Record LOS ANGELES, CA -- (Marketwired) -- 03/13/17 -- ITUS Corporation ("ITUS") (NASDAQ: ITUS) is reminding the investor community that copies of the Prospectus Supplement and related materials for the ITUS rights offering have been filed and mailed and should be available to shareholders of record. ITUS right-holders that do not directly receive the rights offering materials, or are not contacted by their custodian of record within the next few days, should immediately contact MacKenzie Partners, the information agent for the rights offering, at (800) 322-2885 or (212) 929-5500 or by email at ... Read More
View Post

The Delaware Valley Urology Cancer Treatment Center Joins ITUS Early Cancer Detection Biomarker Study

In Business, Government, Healthcare, Legal, Science & Nature by ITUS Corporation

Tech News Keywords: , , , ,

[responsivevoice_button voice="US English Female" buttontext="Play"] / Go to Source Article The Delaware Valley Urology Cancer Treatment Center Joins ITUS Early Cancer Detection Biomarker Study LOS ANGELES, CA -- (Marketwired) -- 03/07/17 -- ITUS Corporation (NASDAQ: ITUS ) today announced that it has enrolled the Delaware Valley Urology Center to be a part of its ongoing Cchek™ cancer biomarker study. Delaware Valley Urology ("DVU") is the largest urology practice in the South Jersey and greater Philadelphia Region, focusing on the advanced diagnosis and treatment of urological conditions including Prost... Read More
View Post

ITUS Announces February 24, 2017 is the Ownership Day for the ITUS Rights Offering

In Business, Emerging Technology, Events, Healthcare, Legal by ITUS Corporation

Tech News Keywords: , , ,

[responsivevoice_button voice="US English Female" buttontext="Play"] / Go to Source Article ITUS Announces February 24, 2017 is the Ownership Day for the ITUS Rights Offering LOS ANGELES, CA -- (Marketwired) -- 02/23/17 -- ITUS Corporation ("ITUS") (NASDAQ: ITUS) announced that Friday, February 24, 2017, is the ownership day for its rights offering. The ownership day is the last day to purchase ITUS shares to be eligible for the ITUS rights offering. Because stock transactions typically take three days to clear, shares that are purchased by 4:00 p.m. Eastern Time on February 24, 2017 will receive a right in the offering. ... Read More
View Post

ITUS Corporation to Present Data at the American Association of Cancer Research National Conference

In Business, Emerging Technology, Events, Healthcare, Legal by ITUS Corporation

Tech News Keywords: , , , , ,

[responsivevoice_button voice="US English Female" buttontext="Play"] / Go to Source Article ITUS Corporation to Present Data at the American Association of Cancer Research National Conference LOS ANGELES, CA -- (Marketwired) -- 02/21/17 -- ITUS Corporation ("ITUS") (NASDAQ: ITUS), a company using the power of the immune system to diagnose cancer, today announced that its abstract titled "Immuno-Profiling Circulating Blood as a Means of Early Detection of Solid Tumors," has been accepted for a presentation at the national conference of the American Association of Cancer Research ("AACR"), which will be held from April 1 to Apri... Read More
View Post

ITUS Announces Common Stock Rights Offering and Ownership Day

In Business, Emerging Technology, Events, Government, Healthcare, Legal by ITUS Corporation

Tech News Keywords: , , , , ,

[responsivevoice_button voice="US English Female" buttontext="Play"] / Go to Source Article LOS ANGELES, CA -- (Marketwired) -- 01/19/17 -- ITUS Corporation ("ITUS") (NASDAQ: ITUS), a company developing Cchek™, a cancer diagnostic platform based on the body's immunological response to a malignancy, today announced that its board of directors has approved a rights offering for ITUS shareholders of up to $12,000,000. The rights offering will include the non-transferable right to purchase one (1) share of ITUS common stock, at a discount, for each share of ITUS common stock owned by shareholders on the ownership day of Friday, February 1... Read More
View Post
Number of Items Identified: 12
Item #Item NameScoreItem Classification
1radio antenna0.741electrical device, radio antenna
2antenna0.774
3electrical device0.774
4device0.774
5steel blue color0.988
6azure color0.808

MD Anderson Cancer Center Joins ITUS Early Cancer Detection Biomarker Study

In Business, Events, Healthcare, Legal by ITUS Corporation

Tech News Keywords: , ,

[responsivevoice_button voice="US English Female" buttontext="Play"] / Go to Source Article LOS ANGELES, CA -- (Marketwired) -- 12/07/16 -- ITUS Corporation (NASDAQ: ITUS) today announced that it has enrolled the MD Anderson Cancer Center at Cooper Hospital in southern New Jersey to be a part of its ongoing cancer biomarker study. "MD Anderson is one of the most well respected names when it comes to cancer," said Dr. Amit Kumar, ITUS's Executive Chairman. "Patient blood samples provided by MD Anderson will assist us in achieving the critical mass that we need to further validate our technology and test benign ... Read More
View Post

ITUS Announces Cchek(TM) Preliminary Cancer Patient Efficacy Study Results

In Business, Events, Healthcare, Legal, Science & Nature by ITUS Corporation

Tech News Keywords: , ,

[responsivevoice_button voice="US English Female" buttontext="Play"] / Go to Source Article LOS ANGELES, CA -- (Marketwired) -- 12/07/16 -- ITUS Corporation ("ITUS") (NASDAQ: ITUS), today announced preliminary results from its Cchek™ cancer patient efficacy study. Using its most recent protocols and methods for measuring a patient's immunological response to a malignancy, the Company achieved Sensitivity of 92% and Specificity of 92% for 88 patient samples, including 54 samples from patients with multiple types and severities of cancer, and 34 healthy patients. During the initial phase of the study, which involved multiple experimenta... Read More
View Post

ITUS Executive Chairman Dr. Amit Kumar Appointed to American Cancer Society National Board of Directors

In Business, Emerging Technology, Events, Government, Healthcare, Legal by ITUS Corporation

Tech News Keywords: , , , ,

[responsivevoice_button voice="US English Female" buttontext="Play"] / Go to Source Article LOS ANGELES, CA -- (Marketwired) -- 11/30/16 -- ITUS Corporation ("ITUS") (NASDAQ: ITUS), today announced that Dr. Amit Kumar, the company's Executive Chairman, has been appointed to serve on the National Board of Directors of the American Cancer Society. The American Cancer Society is the largest voluntary health organization in the United States and is dedicated to eliminating cancer as a major health problem. The American Cancer Society's many activities include: (i) helping people through every step of their cancer experience; (ii) dev... Read More
View Post
Number of Items Identified: 8
Item #Item NameScoreItem Classification
1fan blade0.762device, fan blade
2device0.867
3ventilator0.687device, ventilator
4black color0.86

ITUS Demonstrates Efficacy of its Cchek(TM) Early Cancer Detection Platform with 6 Additional Cancer Types

In Business, Emerging Technology, Events, Healthcare, Legal by ITUS Corporation

Tech News Keywords: , , , ,

[responsivevoice_button voice="US English Female" buttontext="Play"] / Go to Source Article LOS ANGELES, CA -- (Marketwired) -- 11/15/16 -- ITUS Corporation ("ITUS") (NASDAQ: ITUS), today announced that it has successfully utilized its proprietary Cchek™ early cancer detection platform to identify the presence of 6 additional cancer types, including Appendiceal Cancer (cancer of the appendix), Uterine Cancer, Osteosarcoma (cancer of the bone), Leiomyosarcoma (cancer of the soft tissue), Liposarcoma (cancer of the connective tissue), and Vulvar Cancer (cancer of the Vulva). "Although it is still too early to be certain, with eac... Read More
View Post

ITUS Demonstrates Efficacy of its Cchek(TM) Early Cancer Detection Platform with Pancreatic Cancer

In Business, Emerging Technology, Events, Healthcare, Legal by ITUS Corporation

Tech News Keywords: , ,

LOS ANGELES, CA -- (Marketwired) -- 10/25/16 -- ITUS Corporation ("ITUS") (NASDAQ: ITUS), today announced that it has successfully utilized its proprietary Cchek™ early cancer detection platform to identify the presence of Pancreatic Cancer. There is currently no screening test for the early detection of Pancreatic Cancer. Cchek™ is ITUS's proprietary early cancer detection technology which measures a patient's immunological response to a malignancy by detecting the presence, absence, and quantity of certain unique immune system cells that exist in and around a tumor and that enter the blood stream. As part of its ongoing patient efficacy trials, the company has successfully used Cchek™ to dete... Read More
View Post
Number of Items Identified: 4
Item #Item NameScoreItem Classification
1beacon (lighthouse)1tower, beacon (lighthouse)
2tower1
3light brown color0.909
4brick red color0.834

ITUS Hires Michael Catelani as Chief Financial Officer

In Business, Education, Events, Finance, Government, Healthcare, Legal, Science & Nature by ITUS Corporation

Tech News Keywords: , , , , , ,

LOS ANGELES, CA -- (Marketwired) -- 10/24/16 -- ITUS Corporation ("ITUS") (NASDAQ: ITUS), today announced that Michael Catelani has joined the company as its new Chief Financial Officer, effective November 1, 2016. Mr. Catelani replaces Henry Herms, who will retire at the end of December after 21 years with the company. Robert Berman, ITUS's President and CEO, stated, "We owe a debt of gratitude to Henry Herms for his many years of outstanding service to the company. We are pleased to have Mike join ITUS as we continue to build a preeminent biotech company. Mike's expertise with managing the growth and development of life science enterprises will be extremely valuable, and we are excited to add him t... Read More
View Post

ITUS Receives Notice of NASDAQ Continued Listing Compliance

In Business, Emerging Technology, Events, Finance, Healthcare, Legal by ITUS Corporation

Tech News Keywords: , , ,

LOS ANGELES, CA -- (Marketwired) -- 10/17/16 -- ITUS Corporation ("ITUS") (NASDAQ: ITUS), today announced that it has received formal notice from the Listing Qualifications Staff of The NASDAQ Stock Market LLC that the company has evidenced compliance with all requirements for continued listing on The Nasdaq Capital Market. On August 24, 2016, the company was notified by NASDAQ that it no longer met the minimum continued listing requirements, and the August 24 matter is now closed. ITUS is developing Cchek™, a proprietary early cancer detection technology which measures a patient's immunological response to a malignancy by detecting the presence, absence, and quantity of certain unique i... Read More
View Post

ITUS Demonstrates Efficacy of Its Cchek(TM) Early Cancer Detection Platform With Thyroid Cancer

In Business, Emerging Technology, Events, Healthcare, Legal by ITUS Corporation

Tech News Keywords: , ,

LOS ANGELES, CA -- (Marketwired) -- 10/12/16 -- ITUS Corporation ("ITUS") (NASDAQ: ITUS), today announced that it has successfully utilized its proprietary Cchek™ early cancer detection platform to identify the presence of Thyroid Cancer. Thyroid Cancer has been increasing worldwide over the past few decades and is the most rapidly increasing cancer in the U.S. There is currently no screening test for the early detection of Thyroid Cancer. Cchek™ is ITUS's proprietary early cancer detection technology, which measures a patient's immunological response to a malignancy by detecting the presence, absence, and quantity of certain unique immune system cells that exist in and around a tumor and that en... Read More
View Post

ITUS Demonstrates Efficacy of Its Cchek(TM) Early Cancer Detection Platform With Liver Cancer

In Business, Emerging Technology, Events, Healthcare, Legal by ITUS Corporation

Tech News Keywords: , ,

LOS ANGELES, CA -- (Marketwired) -- 10/03/16 -- ITUS Corporation ("ITUS") (NASDAQ: ITUS) today announced that it has successfully utilized its Cchek™ early cancer detection platform to identify the presence of Liver Cancer. Although somewhat rare in the United States, Liver Cancer is the 6th most diagnosed cancer worldwide, and 5th leading cause of cancer deaths. Cchek™ is ITUS's early cancer detection technology which measures a patient's immunological response to a malignancy by detecting the presence, absence, and quantity of certain unique immune system cells that exist in and around a tumor and that enter the blood stream. As part of the ongoing development of ITUS's Cc... Read More
View Post

ITUS Demonstrates Efficacy of Its Cchek(TM) Early Cancer Detection Platform With Ovarian Cancer

In Business, Emerging Technology, Events, Healthcare, Legal by ITUS Corporation

Tech News Keywords: , ,

LOS ANGELES, CA -- (Marketwired) -- 09/30/16 -- ITUS Corporation ("ITUS") (NASDAQ: ITUS), today announced that it has successfully utilized its Cchek™ early cancer detection platform to identify the presence of Ovarian Cancer. There is currently no sufficiently accurate test for the early detection of Ovarian Cancer, which has a 5-year survival rate of only 46%. Cchek™ is ITUS's early cancer detection technology which measures a patient's immunological response to a malignancy by detecting the presence, absence, and quantity of certain unique immune system cells that exist in and around a tumor and that enter the blood stream. As part of the ongoing development of ITUS's Cchek diagnostic platform... Read More
View Post

ITUS Demonstrates Efficacy of Its Cchek(TM) Early Cancer Detection Platform With Melanoma

In Business, Emerging Technology, Events, Healthcare, Legal by ITUS Corporation

Tech News Keywords: , ,

LOS ANGELES, CA -- (Marketwired) -- 09/28/16 -- ITUS Corporation ("ITUS") (NASDAQ: ITUS), today announced that it has successfully utilized its Cchek™ early cancer detection platform to identify the presence of Melanoma. Melanoma accounts for the vast majority of skin cancer deaths, which kills approximately 121,000 people per year worldwide. Cchek™ is ITUS's early cancer detection technology, which measures a patient's immunological response to a malignancy by detecting the presence, absence, and quantity of certain unique immune system cells that exist in and around a tumor and that enter the blood stream. As part of the ongoing development of ITUS's Cchek diagnostic platform, the company has s... Read More
View Post
Number of Items Identified: 6
Item #Item NameScoreItem Classification
1barricade0.803barrier, barricade
2barrier0.852
3news magazine0.6
4magazine0.664
5lemon yellow color1

ITUS Demonstrates Efficacy of Its Cchek(TM) Early Cancer Detection Platform With Colon Cancer

In Business, Events, Healthcare, Legal by ITUS Corporation

Tech News Keywords: , , ,

LOS ANGELES, CA -- (Marketwired) -- 09/26/16 -- ITUS Corporation ("ITUS") (NASDAQ: ITUS), today announced that it has successfully utilized its Cchek™ early cancer detection platform to identify the presence of Colorectal Cancer. The company previously announced success with Breast Cancer and Lung Cancer, which together with Colorectal Cancer, account for the three largest categories of cancer worldwide in terms of incidences. Cchek™ is ITUS's early cancer detection technology for identifying the existence of solid tumors. The technology measures a patient's immune response to a malignancy by detecting the presence, absence, and quantity of certain unique cells that exist in... Read More
View Post

ITUS Extends and Expands Collaborative Research Arrangement With The Wistar Institute

In Business, Education, Events, Healthcare, Legal, Science & Nature by ITUS Corporation

Tech News Keywords: , ,

LOS ANGELES, CA -- (Marketwired) -- 08/15/16 -- ITUS Corporation (NASDAQ: ITUS) today announced that it has extended and expanded its collaboration with The Wistar Institute to further the development of Cchek™, the company's early cancer detection platform. The company is extending its existing arrangement with Wistar, and entering into a new collaboration with Dmitry I. Gabrilovich, M.D. Ph.D., a pioneer in the discovery and study of myeloid derived suppressor cells and the immune system response to cancer. Dr. Amit Kumar, ITUS's Vice Chairman, stated, "Dr. Gabrilovich is a world renowned expert in the study of the tumor microenvironment. His research focuses on understanding ... Read More
View Post
Number of Items Identified: 6
Item #Item NameScoreItem Classification
1barricade0.803barrier, barricade
2barrier0.852
3news magazine0.6
4magazine0.664
5lemon yellow color1

Virtua Healthcare System Joins ITUS Early Cancer Detection Biomarker Study

In Business, Education, Events, Healthcare, Legal by ITUS Corporation

Tech News Keywords: , , , ,

LOS ANGELES, CA -- (Marketwired) -- 07/05/16 -- ITUS Corporation (NASDAQ: ITUS) today announced that it has enrolled Virtua Healthcare System, part of the Penn Medicine Virtua Cancer Program in Southern New Jersey, to be a part of its ongoing cancer biomarker study. "The patient blood samples provided by Virtua will assist us in achieving the critical mass we are looking for across several types of solid tumors," said Dr. Amit Kumar, ITUS's Vice Chairman. "We recently visited with the oncology team at Virtua's state-of-the-art facilities, and we are looking forward to collaborating with Virtua on our cancer study." The Penn Medicine Virtua Cancer Program is accredited by bo... Read More
View Post

ITUS to Ring June 3, 2016 Nasdaq Closing Bell and Launch New Cancer Social Media Campaign

In Business, Events, Finance, Government, Healthcare, Legal by ITUS Corporation

Tech News Keywords: , , , , , , , ,

LOS ANGELES, CA -- (Marketwired) -- 05/31/16 -- ITUS Corporation (NASDAQ: ITUS) today announced that to commemorate National Cancer Survivor's Day on June 5, company representatives will ring the June 3, 2016 closing bell of The Nasdaq Stock Market. The occasion will also mark the official launch of a new cancer social media campaign entitled "Let's Get Crack'n Against Cancer." To honor people affected by cancer, and bring additional focus and a renewed sense of urgency to the ongoing cancer healthcare crisis, the "Let's Get Crack'n Against Cancer" campaign will ask the public to post videos to Twitter, Facebook, and Instagram, indicating why Cancer Counts™ to them, and cracking... Read More
View Post

ITUS Featured on New York Radio Program

In Business, Events, Government, Healthcare, Legal by ITUS Corporation

Tech News Keywords: , , , , ,

LOS ANGELES, CA -- (Marketwired) -- 04/28/16 --  ITUS Corporation ("ITUS") (NASDAQ: ITUS) today announced that its President and CEO, Robert Berman, recently appeared on "Westchester On the Level with Narog and Aris," a news show broadcast by WHYT Radio. During the segment, Mr. Berman is interviewed by the show's host and Yonkers Tribune Editor, Hezi Aris. The appearance covers Cancer4Pres.org, the recently launched cancer advocacy initiative aimed at making the ongoing cancer health crisis a priority for our next president, as well as CChekÔ, the early cancer detection platform being developed by ITUS subsidiary Anixa Diagnostics Corporation.  The segment can be found in the "ITUS in the ... Read More
View Post

ITUS Featured on FOX News Health Segment

In Business, Events, Government, Healthcare, Legal by ITUS Corporation

Tech News Keywords: , , , , , ,

LOS ANGELES, CA -- (Marketwired) -- 04/25/16 -- ITUS Corporation ("ITUS") (NASDAQ: ITUS), today announced that its President and CEO, Robert Berman, recently appeared on a health segment on cancer for FOX News. During the segment, Mr. Berman is interviewed by Fox News Channel's Senior Managing Editor for Health News, Dr. Manny Alveraz. The appearance covers Cancer4Pres.org, the recently launched cancer advocacy initiative aimed at making the ongoing cancer health crisis a priority for our next president, as well as CChek™, the early cancer detection platform being developed by ITUS subsidiary Anixa Diagnostics Corporation.  The segment can be viewed on ITUS's website at www.ITUScorp.com, o... Read More
View Post

ITUS Subsidiary Anixa Diagnostics Corporation Demonstrates Efficacy of Early Cancer Detection Platform With Lung Cancer

In Business, Education, Events, Government, Healthcare, Legal by ITUS Corporation

Tech News Keywords: , , ,

LOS ANGELES, CA -- (Marketwired) -- 04/19/16 -- ITUS Corporation ("ITUS") (NASDAQ: ITUS) today announced that its wholly owned subsidiary, Anixa Diagnostics Corporation, has successfully demonstrated that its Cchek™ early cancer detection platform can be used to identify the presence of lung cancer. The company will now expand its ongoing biomarker study to include additional lung cancer samples. Anixa previously announced results from the study with breast cancer patients.  "The most common method currently used for lung cancer screening is Low Dose Computer Tomography (LDCT), an often ineffective approach that generates numerous false positive results," said Dr. Amit Kumar, ITUS's Executive Chai... Read More
View Post

ITUS Featured on Several National and Local Radio Broadcasts

In Business, Events, Government, Healthcare, Legal by ITUS Corporation

Tech News Keywords: , , , , ,

LOS ANGELES, CA -- (Marketwired) -- 04/14/16 -- ITUS Corporation ("ITUS") (NASDAQ: ITUS) today announced that its President and CEO, Robert Berman, has recently appeared on several national and local radio broadcasts. Most recently, Mr. Berman appeared on NPR affiliate WFUV in New York. Last week, Mr. Berman was an hour-long guest on Joni Aldrich SOS, the iHeartRadio show hosted by nationally acclaimed cancer advocate Joni Aldrich. Other recent appearances include radio station KCHE in Cherokee, Iowa; radio station WOCA in Ocala, Florida; radio station KBUR in San Juan, Texas; and radio station WCHE is Westchester, Pennsylvania. The radio appearances cover a variety of topics including CChek™, the... Read More
View Post
Number of Items Identified: 6
Item #Item NameScoreItem Classification
1barricade0.803barrier, barricade
2barrier0.852
3news magazine0.6
4magazine0.664
5lemon yellow color1

American Cancer Society Vice Chairman of the National Board of Directors, Dr. Arnold Baskies, Joins Scientific Advisory Board for ITUS Subsidiary Anixa Diagnostics Corporation

In Business, Education, Events, Government, Healthcare, Legal, Science & Nature by ITUS Corporation

Tech News Keywords: , , , , , , ,

LOS ANGELES, CA -- (Marketwired) -- 01/25/16 -- ITUS Corporation ("ITUS") (NASDAQ: ITUS), today announced that its wholly owned subsidiary, Anixa Diagnostics Corporation, has added Dr. Arnold Baskies, the Vice Chairman of the Board of Directors of the American Cancer Society, to its Scientific Advisory Board. Dr. Baskies previously served as Chief Science Officer to the Board of Directors of the American Cancer Society and as President of the American Cancer Society of New York and New Jersey. He has been appointed by every New Jersey governor through 2015 to serve as Chair of the New Jersey Governor's Task Force on Cancer Prevention, Early Detection & Treatment. Robert Be... Read More
View Post
Number of Items Identified: 6
Item #Item NameScoreItem Classification
1barricade0.803barrier, barricade
2barrier0.852
3news magazine0.6
4magazine0.664
5lemon yellow color1

ITUS Subsidiary Anixa Diagnostics Corporation Appoints Dr. Michael Shepard to Its Scientific Advisory Board

In Business, Education, Events, Government, Healthcare, Legal, Science & Nature by ITUS Corporation

Tech News Keywords: , , , , , , ,

LOS ANGELES, CA -- (Marketwired) -- 12/07/15 -- ITUS Corporation ("ITUS") (NASDAQ: ITUS), today announced that its wholly owned subsidiary, Anixa Diagnostics Corporation, has added Dr. Michael Shepard to its Scientific Advisory Board. Dr. Shepard is a pioneer in modern cancer research, whose many successes include work that lead to the discovery, development and launch of Herceptin, one of the best-selling cancer drugs of all time, used to treat breast cancer. Cumulative Herceptin sales have totaled more than $50 Billion, including sales in 2014 of greater than $7 Billion. Herceptin's approval opened the door for many other antibody therapies for cancer. For his work in this field, Dr. Shepard received the ... Read More
View Post

ITUS Subsidiary Anixa Diagnostics Corporation Announces Initial Cancer Biomarker Results

In Business, Events, Government, Healthcare, Legal, Science & Nature by ITUS Corporation

Tech News Keywords: , , ,

LOS ANGELES, CA -- (Marketwired) -- 10/05/15 -- ITUS Corporation ("ITUS") (NASDAQ: ITUS), today announced that its wholly owned subsidiary, Anixa Diagnostics Corporation, in collaboration with The Wistar Institute, a National Cancer Institute-designated Cancer Center, has achieved very favorable initial results in a cancer biomarker study, successfully demonstrating the efficacy of Anixa's cancer screening technology. Wistar evaluated blood samples from a small group of patients with differing severities of breast cancer to determine the presence or absence of unique and anomalous biomarkers. Wistar also studied blood samples from a small group of healthy patients. The initial results showed the presence of... Read More
View Post

ITUS Subsidiary Anixa Diagnostics Enters Into Collaborative Research Agreement With The Wistar Institute, a Leading Cancer Research Institute

In Business, Education, Events, Government, Healthcare, Legal, Science & Nature by ITUS Corporation

Tech News Keywords: , , ,

LOS ANGELES, CA -- (Marketwired) -- 07/14/15 -- ITUS Corporation ("ITUS") (NASDAQ: ITUS), today announced that its wholly owned subsidiary, Anixa Diagnostics Corporation, has entered into a Collaborative Research Agreement with The Wistar Institute, located on the campus of the University of Pennsylvania in Philadelphia, Pennsylvania, to further the development of a cancer screening test. Founded in 1892 as the nation's first independent biomedical research institute, Wistar is an international leader in the biomedical research fields of cancer, immunology and infectious diseases, a National Cancer Institute (NCI)-designated Cancer Center, and part of the NCI's select network of national cancer research cen... Read More
View Post

ITUS Announces Uplisting to NASDAQ

In Business, Events, Finance, Government, Healthcare, Legal, Science & Nature by ITUS Corporation

Tech News Keywords: , , , , ,

LOS ANGELES, CA -- (Marketwired) -- 07/09/15 -- ITUS Corporation ("ITUS") (OTCQB: ITUS) today announced that The NASDAQ Stock Market LLC has approved the listing of the Company's stock for trading on The NASDAQ Capital Market. Trading of the Company's securities on The NASDAQ Capital Market will commence effective with the opening of business on Friday, July 10, 2015. Robert Berman, ITUS's President and CEO, stated, "NASDAQ is the market where shares of the world's most innovative and successful, high-tech companies are traded. With the potentially life saving technologies we are developing at Anixa, our cancer diagnostic subsidiary, and plans for other high-tech initiatives, NASDAQ is exactly where ... Read More
View Post

ITUS Announces Reverse Stock Split With the Intention to List Shares on NASDAQ

In Business, Events, Finance, Government, Healthcare, Legal, Science & Nature by ITUS Corporation

Tech News Keywords: , , , , , ,

LOS ANGELES, CA -- (Marketwired) -- 06/25/15 -- ITUS Corporation ("ITUS") (OTCQB: ITUS), today announced that effective at 9:00 a.m. Eastern Standard Time on Friday, June 26, 2015, the company will implement a 1 for 25 reverse stock split of its common shares. The company's common stock will begin trading on a post-reverse stock split basis on the OTCQB under the temporary symbol "ITUSD" effective with the open of business on June 26, 2015. The company's shareholders approved implementation of a reverse stock split on August 8, 2014, and the company's board of directors has determined to take such action to help the company become eligible for listing on The NASDAQ Stock Market. Robert Berman, ITUS's... Read More
View Post

ITUS Announces Formation of Cancer Diagnostics Subsidiary

In Business, Education, Events, Government, Healthcare, Legal, Science & Nature by ITUS Corporation

Tech News Keywords: , , , , , , ,

LOS ANGELES, CA -- (Marketwired) -- 06/23/15 -- ITUS Corporation ("ITUS") (OTCQB: ITUS), today announced that it has formed a new subsidiary, Anixa Diagnostics Corporation ("Anixa"), for the purpose of developing and marketing non-invasive, early cancer screening tests. Anixa will be lead by Dr. Amit Kumar, who will become Executive Chairman of Anixa, and also assume the role of Vice-Chairman of ITUS. Robert Berman, ITUS's President and CEO, stated, "Dr. Kumar has many years of experience in cancer diagnostics, is a foremost expert in the utilization of cutting edge technolgies for early cancer screening, and has successfully developed and guided several cancer diagnostic tests through the approval p... Read More